drugset / Trial / NCT07072221
Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of bendamustine combined with chidamide and lenalidomide in R/R PTCL patients.
Timeline
- Start
- 2024-11-01
- Primary completion
- 2029-08-01
- Completion
- 2029-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustine | Small molecule | 70 mg/m2 | Intravenous |
| Subject | Bendamustine | Small molecule | 90 mg/m2 | Intravenous |
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |
| Subject | Tucidinostat | Small molecule | 15 mg | Oral |
| Subject | Tucidinostat | Small molecule | 20 mg | Oral |